FIRE-4 (AIO KRK-0114): Efficacy of third-line rechallenge with cetuximab versus investigator’s choice in relation to the interval between initial and third-line anti-EGFR therapy.
Year: 2026
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Lena Weiss, Sebastian Stintzing, Ludwig Fischer Von Weikersthal, Florian Kaiser, Martin Fuchs, Gerald W. Prager, Kathrin Heinrich, Andreas Dickhut, Ralf Hofheinz, Thomas Decker, Stefan Angermeier, Tom Ganten, Christof Burkart, Matthias Sandmann, Leopold Öhler, Dora Niedersuess-Beke, Thomas Kubin, Dominik Paul Modest, Swantje Held, Volker Heinemann
Institutions: LMU Klinikum, Ludwig-Maximilians-Universität München, Stiftung Charité, Charité - Universitätsmedizin Berlin, Roland Mills United (Germany), München Klinik Bogenhausen, Klinikum Fulda, Klinikum Ludwigsburg, Schwarzwald-Baar Klinikum, Helios Universitätsklinikum Wuppertal, St. Josef-Krankenhaus Wien, Wilhelminen Hospital, AIO Studien gGmbH
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W7162565537
Cites:
Cited by:
Related to: